Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Nov 2023: Trial registered, NCT06150924
  2. 14 Dec 2023: Trial started, NCT06150924

The trials

NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

State
Completed
Phase
Phase 2
People
60 taking part
Started
14 Dec 2023
Primary completion
27 Feb 2025
Arms
Cohort 2
Results
Posted on the registry
  1. 29 Nov 2023: Trial registered
  2. 14 Dec 2023: Trial started
  3. 23 Apr 2025: Trial completed
  4. 3 Jun 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.